These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 25030510)

  • 1. Does neurology need a faster FDA?
    Burton A
    Lancet Neurol; 2014 Aug; 13(8):760-1. PubMed ID: 25030510
    [No Abstract]   [Full Text] [Related]  

  • 2. New fee structure proposed by FDA might lead to more talk.
    Waters H
    Nat Med; 2011 Oct; 17(10):1159. PubMed ID: 21988966
    [No Abstract]   [Full Text] [Related]  

  • 3. Where do our priorities lie?
    Hanauer SB
    Nat Clin Pract Gastroenterol Hepatol; 2007 Jul; 4(7):353. PubMed ID: 17607292
    [No Abstract]   [Full Text] [Related]  

  • 4. US FDA feels the heat from Congressional hearings.
    Loewenberg S
    Lancet; 2008 May; 371(9624):1565-6. PubMed ID: 18476294
    [No Abstract]   [Full Text] [Related]  

  • 5. FDA joins market.
    Gershon D
    Nature; 1993 Jul; 364(6433):93. PubMed ID: 8321293
    [No Abstract]   [Full Text] [Related]  

  • 6. The marketplace can't give us the drug safety data we need.
    Avorn J
    MedGenMed; 2007 Feb; 9(1):29. PubMed ID: 17435636
    [No Abstract]   [Full Text] [Related]  

  • 7. User fees to hasten FDA review.
    Gershon D
    Nature; 1992 Oct; 359(6396):567. PubMed ID: 1406982
    [No Abstract]   [Full Text] [Related]  

  • 8. User fees for faster drug reviews. Are they helping or hurting the public health?
    Thompson L
    FDA Consum; 2000; 34(5):25-9. PubMed ID: 11590789
    [No Abstract]   [Full Text] [Related]  

  • 9. Drug safety special: the safety catch.
    Wadman M
    Nature; 2005 Mar; 434(7033):554-6. PubMed ID: 15800591
    [No Abstract]   [Full Text] [Related]  

  • 10. User fees to fund faster reviews.
    Henkel J
    FDA Consum; 1993 Oct; 27(8):19-21. PubMed ID: 10129049
    [No Abstract]   [Full Text] [Related]  

  • 11. Drug safety on trial.
    Nature; 2005 Mar; 434(7033):545. PubMed ID: 15800579
    [No Abstract]   [Full Text] [Related]  

  • 12. New leadership for the FDA.
    Lancet; 2002 Oct; 360(9341):1183. PubMed ID: 12401238
    [No Abstract]   [Full Text] [Related]  

  • 13. Financial conflicts of interest are related to voting patterns at FDA Advisory Committee meetings.
    Lurie P
    MedGenMed; 2006 Oct; 8(4):22. PubMed ID: 17415305
    [No Abstract]   [Full Text] [Related]  

  • 14. Drug development for neglected diseases - the trouble with FDA review vouchers.
    Kesselheim AS
    N Engl J Med; 2008 Nov; 359(19):1981-3. PubMed ID: 18987367
    [No Abstract]   [Full Text] [Related]  

  • 15. The Prescription Drug User Fee Act: is a faster Food and Drug Administration always a better Food and Drug Administration?
    Zelenay JL
    Food Drug Law J; 2005; 60(2):261-338. PubMed ID: 16094773
    [No Abstract]   [Full Text] [Related]  

  • 16. Drug safety reform at the FDA--pendulum swing or systematic improvement?
    McClellan M
    N Engl J Med; 2007 Apr; 356(17):1700-2. PubMed ID: 17435081
    [No Abstract]   [Full Text] [Related]  

  • 17. Controversy still swirls around FDA user fees: since 1992, the prescription drug user fee act and reauthorizations have sped up new drug approvals--but does speed equal safety?
    Ullman K
    Ann Neurol; 2013 Nov; 74(5):A10-1. PubMed ID: 24353218
    [No Abstract]   [Full Text] [Related]  

  • 18. Letter from the Commissioner's Office at the US FDA.
    Vernon JA
    Pharmacoeconomics; 2007; 25(4):267-8. PubMed ID: 17402801
    [No Abstract]   [Full Text] [Related]  

  • 19. Paying for drug approvals--who's using whom?
    Avorn J
    N Engl J Med; 2007 Apr; 356(17):1697-700. PubMed ID: 17435083
    [No Abstract]   [Full Text] [Related]  

  • 20. A proposal for radical changes in the drug-approval process.
    Wood AJ
    N Engl J Med; 2006 Aug; 355(6):618-23. PubMed ID: 16899784
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.